Search research articles
Contact Us
Filters
Showing results (51-60 of 89) with videos related to
Page
of 9
Sort By:
Annals of Surgical Oncology
|
April 4, 2021
Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma
Michele Reni, Julia Braverman, Andrew Hendifar, et al.
JCO Precision Oncology
|
July 28, 2018
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation
Rachna T Shroff, Andrew Hendifar, Robert R McWilliams, et al.
Scientific Reports
|
September 2, 2022
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
Jun Gong, Shant Thomassian, Sungjin Kim, et al.
Pancreas
|
October 2, 2023
Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome
Neil R Sharma, Simon K Lo, Andrew Hendifar, et al.
Research Square
|
December 11, 2023
Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity
Hayato Muranaka, Sandrine Billet, Carlos Cruz-Hernández, et al.
Nature Cancer
|
January 22, 2024
The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients
Arsen Osipov, Ognjen Nikolic, Arkadiusz Gertych, et al.
JCO Precision Oncology
|
September 3, 2021
Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
Andrew Hendifar, Edik M Blais, Brian Wolpin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2018
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
Jonathan Strosberg, Edward Wolin, Beth Chasen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 7, 2017
Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D Singhi, Siraj M Ali, Jill Lacy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2014
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
Jean-Yves Blay, Michael G Leahy, Binh Bui Nguyen, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 89) with videos related to
Sort By:
Page
of 9
Annals of Surgical Oncology
|
April 4, 2021
Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma
Michele Reni, Julia Braverman, Andrew Hendifar, et al.
JCO Precision Oncology
|
July 28, 2018
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation
Rachna T Shroff, Andrew Hendifar, Robert R McWilliams, et al.
Scientific Reports
|
September 2, 2022
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
Jun Gong, Shant Thomassian, Sungjin Kim, et al.
Pancreas
|
October 2, 2023
Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome
Neil R Sharma, Simon K Lo, Andrew Hendifar, et al.
Research Square
|
December 11, 2023
Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity
Hayato Muranaka, Sandrine Billet, Carlos Cruz-Hernández, et al.
Nature Cancer
|
January 22, 2024
The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients
Arsen Osipov, Ognjen Nikolic, Arkadiusz Gertych, et al.
JCO Precision Oncology
|
September 3, 2021
Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
Andrew Hendifar, Edik M Blais, Brian Wolpin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2018
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
Jonathan Strosberg, Edward Wolin, Beth Chasen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 7, 2017
Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D Singhi, Siraj M Ali, Jill Lacy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2014
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
Jean-Yves Blay, Michael G Leahy, Binh Bui Nguyen, et al.
Page
of 9